FYN

Across TCGA pan-cancer cohorts, FYN mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of FYN’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FYN mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FYN is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where FYN tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FYN mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.282	<.001	10	view →
LUAD	Female	II,III,IV	−0.915	<.001	9	view →
LSCC	Male	II,III,IV	−0.820	<.001	8	view →
COAD	All	All	−0.310	<.001	5	view →
PDAC	Female	All	+0.438	.001	3	view →
HNSC	All	III,IV	−0.186	.011	3	view →
OV	All	All	−1.026	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

FYN–CCRCC

Open the CCRCC breakdown →